Subsequent analysis demonstrated that elevated NCBP2 expression was linked to improved survival rates and response to anti-PD-L1 therapy in bladder cancer, whereas it was associated with poorer survival outcomes in melanoma. The gene discussed is NCBP2; the disease is urinary bladder cancer.